MyAverix Finance
SHG · Healthcare
Nanjing Well Pharmaceutical Co Ltd (603351)
Drug Manufacturers - Specialty & Generic
Nanjing Well Pharmaceutical Co Ltd (603351) is listed on SHG in the Healthcare sector. Industry: Drug Manufacturers - Specialty & Generic. As of 2026-03-29, reported market cap is $3.36B, P/E ratio is 22.73, net margin is 11.2%. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.
Key metrics for 603351
Nanjing Well Pharmaceutical Co Ltd (603351) — FAQ
What is Nanjing Well Pharmaceutical Co Ltd's market cap?
Nanjing Well Pharmaceutical Co Ltd (603351) has a reported market cap of $3.36B (data as of 2026-03-29).
What is 603351's P/E ratio?
The price-to-earnings (P/E) ratio for Nanjing Well Pharmaceutical Co Ltd (603351) is 22.73 (data as of 2026-03-29).
Does Nanjing Well Pharmaceutical Co Ltd pay a dividend?
Dividend yield is not available in the current snapshot for Nanjing Well Pharmaceutical Co Ltd (603351). Check the MyAverix Finance app for the latest dividend data.
What sector is Nanjing Well Pharmaceutical Co Ltd in?
Nanjing Well Pharmaceutical Co Ltd (603351) is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).
What exchange is 603351 listed on?
603351 is listed on SHG.
What is Nanjing Well Pharmaceutical Co Ltd's net margin?
Nanjing Well Pharmaceutical Co Ltd (603351) reports a net margin of 11.2% (data as of 2026-03-29).
Full report in the app
Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.